NCT06193148View on ClinicalTrials.gov

A Study to Evaluate the Effect of Jaktinib on QT/QTc Interval in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 19, 2024

Primary Completion Date

June 18, 2024

Study Completion Date

June 18, 2024

Conditions
Healthy Participants
Interventions
DRUG

Jaktinib

Participants will receive Jaktinib orally for single dose

DRUG

Placebo

Participants will receive Placebo orally for single dose

Trial Locations (1)

Unknown

The First Affiliated Hospital of Soochow University, Suzhu

All Listed Sponsors
lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY

NCT06193148 - A Study to Evaluate the Effect of Jaktinib on QT/QTc Interval in Healthy Participants | Biotech Hunter | Biotech Hunter